MedTrace Logo

Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer

NCT07776171 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2026-08-20

No results posted yet for this study

Summary

This study is a randomized, open-label, controlled phase II clinical trial.

It is planned to enroll 176 subjects with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer previously treated with Poly (ADP-ribose) polymerase inhibitors (PARPi).

Subjects will be randomly assigned in a 1:1 ratio to receive either the experimental treatment group (trastuzumab Rezetecan + carboplatin ± bevacizumab) or the control treatment group (investigator's choice chemotherapy ± bevacizumab).

Conditions

Interventions

DRUG

Trastuzumab Rezetecan (SHR-A1811)

Administered intravenously on Day 1 of each 3-week treatment cycle.

DRUG

Carboplatin

Administered intravenously on Day 1 of each 3-week treatment cycle.

DRUG

Bevacizumab

Administered intravenously on Day 1 of each 3-week treatment cycle.

DRUG

Bevacizumab

Administered intravenously.

DRUG

Carboplatin + Paclitaxel

Administered intravenously.

DRUG

Carboplatin + pegylated liposomal doxorubicin

Administered intravenously.

DRUG

Carboplatin + Gemcitabine

Administered intravenously

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-03-30
Completion
2030-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07776171 on ClinicalTrials.gov